The analysis revealed significantly reduced promoter methylation levels for both CCL18 and EGF in primary breast tumor samples relative to normal breast tissues (normal n = 97; tumor n = 793; p < 0.05) (Figure 6a,b). This evidence concerns the gene CCL18 and breast neoplasm.